Medicare Zepbound Cost What You Need to Know

Understanding Zepbound and Its FDA-Approved Uses Under Medicare

Zepbound is a GLP-1 receptor agonist medication designed to regulate blood sugar and facilitate weight management. GLP-1 medications like Zepbound work by mimicking a natural hormone that helps control appetite and metabolism. In December 2024, the U.S. Food and Drug Administration (FDA) approved Zepbound specifically for use in adults with obstructive sleep apnea (OSA) who also have a body mass index (BMI) of 27 or higher. While Zepbound is also indicated for chronic weight management, its main Medicare coverage hinges on its FDA-approved use for OSA, not general obesity treatment.

Why does this distinction matter? Medicare coverage depends greatly on FDA indication. Medications approved for weight loss or obesity management are excluded from Medicare Part D and Medicare Advantage plans per longstanding legislative rules. However, once Zepbound received approval for OSA, it became eligible for coverage under Medicare plans—but solely for this specific condition. This nuanced difference has big implications for patients and their out-of-pocket costs.

Current Medicare Coverage Landscape for Zepbound in 2025

In 2025, Zepbound is covered under Medicare Part D and most Medicare Advantage plans, but only if prescribed for obstructive sleep apnea, a condition that now meets the current FDA-approved criteria. If your doctor prescribes Zepbound solely for weight loss or general obesity management, you are unlikely to receive coverage due to explicit anti-obesity medication (AOM) legislative exclusions built into Medicare’s rules. These exclusions have been central in debates about broadening access to GLP-1 medications for conditions beyond diabetes and OSA.

There is significant variability among state Medicaid plans as well. For instance, some states, like California, have expanded their Medicaid (Medi-Cal) coverage to include Zepbound for OSA without a need for prior authorization, though coverage for obesity management remains highly restricted in most states. Retirees with supplemental Medigap or private Medicare Advantage plans might have different experiences, especially if their plans offer extended pharmacy benefits or specific exceptions for FDA-approved uses.

Detailed Breakdown of Zepbound Costs Under Medicare

The financial aspect of using Zepbound under Medicare can be complex, involving a combination of medication list price, deductibles, and out-of-pocket (OOP) maximums. Let’s break down the costs for 2025:

Cost Component	Amount (2025)	Implications
List Price (per month)	$1,086	Base retail cost of Zepbound injector pens
Medicare Part D Deductible	$590 (annual)	Paid before Medicare starts covering prescription drugs
Out-of-Pocket Maximum (OOP)	$2,000 (annual)	Cap on covered prescription expenses under Part D
Zepbound Savings Card/Copay Assistance	As low as $25/month (with insurance, until end of 2025)	Reduces monthly copays, but expires at the end of 2025

For Medicare beneficiaries with OSA prescribed Zepbound, expenses will be subject to the Part D deductible and copays or coinsurance. But the total out-of-pocket amount paid for all prescription drugs, including Zepbound, cannot exceed $2,000 annually in 2025. Patients without any coverage will face the full list price—plus any dispensing or pharmacy fees, making affordability a real concern. For more details on how Medicare sets these limits, see the article on Medicare reimbursement.

Financial Assistance Programs and Savings Opportunities for Zepbound Users

Lilly, the manufacturer of Zepbound, offers a Savings Card program to eligible users with commercial insurance, sometimes reducing monthly copays to as little as $25. This generous copay assistance is scheduled to expire at the end of 2025. Additional financial support may come from manufacturer discount programs or assistance funds provided through nonprofit patient advocacy organizations.

However, these savings programs have their limits. They usually do not apply to patients enrolled in government insurance programs, such as Medicare or Medicaid, due to legal restrictions. For patients who are either uninsured or underinsured, some alternatives might include seeking support from charitable foundations, shopping for pharmacy coupons, or discussing with healthcare providers whether other covered medications could be suitable. Still, few options reduce the high list price for those outside targeted assistance programs.

For those interested in finding the right Medicare coverage during open enrollment, learning more at open enrollment for Medicare can be very helpful.

Recent CMS Proposed Rule Changes and Their Potential Effect on Zepbound Coverage in 2026

The Centers for Medicare & Medicaid Services (CMS) has issued proposed rule changes in early 2024 that would dramatically alter the future landscape of anti-obesity medication coverage. If finalized, these rules will allow Medicare to cover AOMs, including Zepbound, for beneficiaries diagnosed with obesity—even when not linked to an additional condition like OSA.

Timeline and expected impact:

• 2024: CMS proposes broadened coverage for anti-obesity medications.
• 2025: Medicare still only covers Zepbound for OSA; no weight-loss coverage yet.
• 2026: If rules are finalized, Zepbound could be covered for weight loss/obesity management for millions of Medicare recipients diagnosed with obesity.

This would further influence plan formularies and patient access, giving prescribers and patients more treatment options and potentially reducing out-of-pocket costs for a large group of Medicare enrollees. Stay tuned to ongoing Medicare updates for the latest details as these proposed rules move toward final adoption.

Variations in Coverage: Medicare vs. Medicaid vs. Private Plans

Certain patients will experience different coverage scenarios depending on which insurance they use. For instance, Medicaid coverage for Zepbound varies widely from state to state:

1. California Medi-Cal: Covers Zepbound for OSA without requiring prior authorization. However, weight-loss coverage is restricted and must follow strict criteria.
2. Other states: May not cover Zepbound at all outside of OSA or have lengthy prior authorization requirements for other indications.

Private insurance plans are also constantly evolving in response to high costs and increasing demand for GLP-1 medications like Zepbound. As of July 1, 2025, CVS Caremark—a major pharmacy benefit manager—will remove Zepbound from some non-Medicare plan formularies due to cost pressures. This example of formulary removal underscores how even those with private or employer insurance may find it more difficult to access Zepbound at an affordable price.

For coverage of off-label indications, or for those seeking Zepbound due to obesity rather than OSA, most plans remain restrictive unless CMS rule changes take effect. Always check your plan’s latest drug list and appeals process for coverage details.

Real-World Examples: How Medicare Coverage Affects Zepbound Patients

Let’s look at three patient stories to illustrate how Medicare, Medicaid, and private coverage for Zepbound plays out in practice:

• Case 1: Medicare Patient with OSA: Mary is a 66-year-old retiree with Medicare Advantage who’s recently diagnosed with moderate OSA. Her physician prescribes Zepbound, and her Part D plan covers it since OSA is a qualifying FDA-approved use. After her $590 deductible, her out-of-pocket costs apply toward a $2,000 annual maximum, making her costs predictable and capped.
• Case 2: Medicare Patient Seeking Weight Loss: Joe, also on Medicare, wants Zepbound for chronic weight management. He learns that his plan refuses coverage since anti-obesity medications aren’t approved for weight loss alone under Medicare until potential CMS changes in 2026. Joe must pay the full $1,086/month unless he can temporarily use a manufacturer’s discount before it expires.
• Case 3: Medicaid in California: Ana, a Medi-Cal (California Medicaid) recipient, receives a prescription for Zepbound for OSA. Medi-Cal covers her medication without prior authorization, so Ana pays only a small pharmacy copay. However, if her doctor had prescribed Zepbound for weight management, coverage would be uncertain and likely denied.

These case studies highlight the importance of knowing both your insurance plan’s drug coverage criteria and the specific diagnosis driving your prescription.

Checking Your Coverage: How to Confirm Zepbound Inclusion in Your Medicare Plan

If you’ve been prescribed Zepbound, follow these steps to confirm whether your Medicare Part D or Medicare Advantage plan will cover it:

1. Log in to your Medicare plan provider’s member portal (see Medicare sign in details for guidance).
2. Access the most updated prescription drug formulary for your specific plan year.
3. Search for “Zepbound” and check listed indications—ensure coverage is listed for obstructive sleep apnea (OSA).
4. If you’re unsure or see conflicting information, call your plan’s customer service or pharmacist directly. You may also call the official Medicare questions phone number for assistance.
5. Confirm whether any prior authorization or supporting medical documentation is required.

Be sure to confirm that your prescription matches the approved indication for coverage—currently OSA—as off-label uses are not covered by Medicare as of 2025.

FAQ: Common Questions About Medicare Zepbound Cost and Coverage

How can I check if my Medicare Part D plan covers Zepbound?

Check your plan’s online formulary or call your plan provider directly. You can find additional help in navigating these resources on your railroad Medicare provider portal or plan’s member portal.

What are the out-of-pocket costs for Zepbound without insurance?

Without insurance, expect to pay the list price of approximately $1,086 per month, plus any pharmacy fees. Financial assistance programs may be unavailable if you have government coverage.

Are there any discounts or savings cards available for Zepbound?

Yes. The Zepbound Savings Card often reduces copays to as low as $25 per month for commercially insured patients. This card is not available for Medicare enrollees, and current offerings expire at the end of 2025.

How does the proposed CMS reinterpretation affect Zepbound coverage?

Beginning in 2026, if the CMS proposed rule changes are finalized, Medicare will be able to cover anti-obesity medications like Zepbound for beneficiaries diagnosed with obesity, greatly broadening coverage and potentially lowering out-of-pocket costs.

What conditions must be met for Medicare to cover Zepbound?

As of 2025, Medicare will only cover Zepbound for patients with obstructive sleep apnea (OSA) when prescribed according to FDA approval. Broader obesity management coverage is only expected if and when CMS expands its policy in 2026.

Key Takeaways: Navigating Medicare Coverage and Costs for Zepbound in 2025 and Beyond

For now, Medicare’s coverage for Zepbound is strictly for obstructive sleep apnea (OSA) with a corresponding diagnosis. Coverage for weight management or obesity alone remains excluded through the end of 2025. Patients must be aware of the high list price ($1,086 per month) if not covered, though a cap on out-of-pocket expenses ($2,000 per year) helps many.

Strategies to manage costs include:

• Maximizing use of insurance and copay assistance (before expiration in 2025)
• Monitoring new Medicare updates and CMS rule changes
• Checking your plan’s formulary regularly for any updates, additions, or formulary removals
• Working closely with your care team to match your prescription to USDA-approved indications

The policy landscape is changing rapidly, and staying informed can make a substantial difference in both access and affordability. For additional advice, tools, or guidance on all things Medicare, see more about open enrollment for Medicare and plan to revisit your coverage every year.